Endoxifen in Treatment of Individuals with Borderline Personality Disorder with Predominant Impulsivity: A Case Series

Abstract

Endoxifen, a protein kinase C inhibitor, has been approved for use in manic episodes in India. One of the symptom traits that it predominantly targets is impulsivity. Impulsivity can also be a symptom dimension of other mental health conditions, one of which is Borderline Personality Disorder (BPD). Management of BPD is challenging, with limited pharmacological options that are symptom-directed and psychotherapy sessions that are fraught with early dropouts and lack of compliance. Impulsive behaviors represent a major reason for seeking help in BPD, especially with regard to non-suicidal self-injury, substance abuse, high-risk sexual behavior, aggression, etc. Here, we present a case series comprising five individuals with a diagnosis of BPD whose treatment regimens were changed and endoxifen added at a dose of 8 mg once daily. Clinical improvement was monitored using the Borderline Evaluation of Severity Over Time (BEST). All the subjects improved in the impulsivity domains as well as with regard to attention deficits, mood fluctuations, and overall functioning. Endoxifen is thus potential promising in terms of the management of BPD, but needs more extensive study to fully substantiate its clinical benefits.

Keywords

borderline personality disorder / impulsivity / protein kinase C / endoxifen / case series

References

[1] Bozzatello P, Rocca P, De Rosa ML, Bellino S. Current and emerging medications for borderline personality disorder: is pharmacotherapy alone enough? Expert Opin Pharmacother. 2020;21(1):47–61. doi: 10.1080/14656566.2019.1686482.

[2] Guilé JM, Boissel L, Alaux-Cantin S, de La Rivière SG. Borderline personality disorder in adolescents: prevalence, diagnosis, and treatment strategies. Adolesc Health Med Ther. 2018;9:199–210. doi: 10.2147/AHMT.S156565.

[3] Choi-Kain LW, Finch EF, Masland SR, et al. What works in the treatment of borderline personality disorder. Curr Behav Neurosci Rep. 2017;4(1):21–30. doi: 10.1007/s40473-017-0103-z.

[4] Leichsenring F, Leibing E, Kruse J, et al. Borderline personality disorder. Lancet. 2011;377(9759):74–84. doi: 10.1016/S0140-6736(10)61422-5.

[5] Ahmad A, Sheikh S, Shah T, et al. Endoxifen, a new treatment option for mania: a double-blind, active-controlled trial demonstrates the antimanic efficacy of endoxifen. Clin Transl Sci. 2016;9(5):252–259. doi: 10.1111/cts.12407. Erratum in: Clin Transl Sci. 2017;10(2):117.

[6] Thanvi V. Real-world long-term experience on endoxifen in bipolar disorder with psychotic symptoms. Case Rep Psychiatry. 2022;2022:3684181. doi: 10.1155/2022/3684181.

[7] Pfohl B, Blum N, St John D, et al. Reliability and validity of the Borderline Evaluation of Severity Over Time (BEST): a self-rated scale to measure severity and change in persons with borderline personality disorder. J Pers Disord. 2009;23(3):281–293. doi: 10.1521/pedi.2009.23.3.281.

[8] Akiskal HS. Validating ‘hard’ and ‘soft’ phenotypes within the bipolar spectrum: continuity or discontinuity? J Affect Disord. 2003;73(1–2):1–5. doi: 10.1016/s0165-0327(02)00390-7.

[9] Krause-Utz A, Erol E, Brousianou AV, et al. Self-reported impulsivity in women with borderline personality disorder: the role of childhood maltreatment severity and emotion regulation difficulties. Borderline Personal Disord Emot Dysregul. 2019;6:6. doi: 10.1186/s40479-019-0101-8.

[10] Eskander N, Emamy M, Saad-Omer SM, et al. The impact of impulsivity and emotional dysregulation on comorbid bipolar disorder and borderline personality disorder. Cureus. 2020;12(8):e9581. doi: 10.7759/cureus.9581.

[11] Saunders KEA, Jones T, Perry A, et al. The influence of borderline personality traits on clinical outcomes in bipolar disorder. Bipolar Disord. 2021;23(4):368–375. doi: 10.1111/bdi.12978.

[12] Prado-Lima PA. Tratamento farmacológico da impulsividade e do comportamento agressivo [Pharmacological treatment of impulsivity and aggressive behavior]. Braz J Psychiatry. 2009;31 Suppl 2:S58–65. doi: 10.1590/s1516-44462009000600004. Portuguese.

[13] Chanen AM, Thompson KN. Prescribing and borderline personality disorder. Aust Prescr. 2016;39(2):49–53. doi: 10.18773/austprescr.2016.019.

[14] Bellino S, Bozzatello P, Brignolo E, Bogetto F. Antipsychotics in the treatment of impulsivity in personality disorders and impulse control disorders. Current Psychopharmacology. 2013;2(1):5–17. doi: 10.2174/2211556011302010005

[15] Kim S, Lee D. Prefrontal cortex and impulsive decision making. Biol Psychiatry. 2011;69(12):1140–1146. doi: 10.1016/j.biopsych.2010.07.005.

[16] Birnbaum SG, Yuan PX, Wang M, et al. Protein kinase C overactivity impairs prefrontal cortical regulation of working memory. Science. 2004;306(5697):882–884. doi: 10.1126/science.1100021.

[17] Ahmad A, Sheikh S, Khan MA, et al. Endoxifen: A new, protein kinase C inhibitor to treat acute and mixed mania associated with bipolar I disorder. Bipolar Disord. 2021;23(6):595–603. doi: 10.1111/bdi.13041.

[18] Committee Opinion No. 601: Tamoxifen and uterine cancer. Obstet Gynecol. 2014;123(6):1394–1397. doi: 10.1097/01.AOG.0000450757.

[19] Goetz MP, Suman VJ, Reid JM, et al. First-in-human phase I study of the tamoxifen metabolite z-endoxifen in women with endocrine-refractory metastatic breast cancer. J Clin Oncol. 2017;35(30):3391–3400. doi: 10.1200/JCO.2017.73.3246.

[20] Garg S. First report of endoxifen treatment for 1 year: a case report of bipolar disorder. Int J Multispecialty Health. 2022;8(5):1–4. DOI 10.5281/zenodo.6596684.

[21] Gowda M, Dewani K. Cost-effectiveness of endoxifen therapy in severe psychotic bipolar I disorder: a case report. Int J Appl Res. 2022;8(8):09–13.

RIGHTS & PERMISSIONS

Banerjee D., Ray R.